Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.

Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E, Borley N, Keating D, Page EC, Saya S, Hazell S, Livni N, deSouza N, Neal D, Hamdy FC, Kumar P, Antoniou AC, Kote-Jarai Z; PROFILE Study Steering Committee, Eeles RA.

Oncologist. 2016 Jun;21(6):716-22. doi: 10.1634/theoncologist.2015-0336. Epub 2016 May 5.


Prediction models and risk assessment for silicosis using a retrospective cohort study among workers exposed to silica in China.

Tse LA, Dai J, Chen M, Liu Y, Zhang H, Wong TW, Leung CC, Kromhout H, Meijer E, Liu S, Wang F, Yu IT, Shen H, Chen W.

Sci Rep. 2015 Jun 19;5:11059. doi: 10.1038/srep11059.


A genetic-based approach to personalized prostate cancer screening and treatment.

Helfand BT, Catalona WJ, Xu J.

Curr Opin Urol. 2015 Jan;25(1):53-8. doi: 10.1097/MOU.0000000000000130. Review.


A review of cancer risk prediction models with genetic variants.

Wang X, Oldani MJ, Zhao X, Huang X, Qian D.

Cancer Inform. 2014 Sep 21;13(Suppl 2):19-28. doi: 10.4137/CIN.S13788. eCollection 2014. Review.


Prostate cancer in young men: an important clinical entity.

Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA.

Nat Rev Urol. 2014 Jun;11(6):317-23. doi: 10.1038/nrurol.2014.91. Epub 2014 May 13. Review.


The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Van den Broeck T, Joniau S, Clinckemalie L, Helsen C, Prekovic S, Spans L, Tosco L, Van Poppel H, Claessens F.

Biomed Res Int. 2014;2014:627510. doi: 10.1155/2014/627510. Epub 2014 Feb 19. Review.


Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men.

Na R, Liu F, Zhang P, Ye D, Xu C, Shao Q, Qi J, Wang X, Chen Z, Wang M, He D, Wang Z, Zhou F, Yuan J, Gao X, Wei Q, Yang J, Jiao Y, Ou-Yang J, Zhu Y, Wu Q, Chen H, Lu D, Shi R, Lin X, Jiang H, Wang Z, Jiang D, Sun J, Zheng SL, Ding Q, Mo Z, Sun Y, Xu J.

Prostate. 2013 Nov;73(15):1623-35. doi: 10.1002/pros.22629. Epub 2013 Sep 9.


Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.

Ren S, Xu J, Zhou T, Jiang H, Chen H, Liu F, Na R, Zhang L, Wu Y, Sun J, Yang B, Gao X, Zheng SL, Xu C, Ding Q, Sun Y.

Prostate. 2013 Dec;73(16):1824-35. doi: 10.1002/pros.22721. Epub 2013 Aug 26.


Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.

Jiang H, Liu F, Wang Z, Na R, Zhang L, Wu Y, Zheng J, Lin X, Jiang D, Sun J, Zheng SL, Ding Q, Xu J.

Prostate. 2013 Nov;73(15):1651-9. doi: 10.1002/pros.22661. Epub 2013 Jul 18.


Prostate cancer risk-associated genetic markers and their potential clinical utility.

Xu J, Sun J, Zheng SL.

Asian J Androl. 2013 May;15(3):314-22. doi: 10.1038/aja.2013.42. Epub 2013 Apr 8.


Utility of single nucleotide polymorphisms in prostate biopsy decisions.

Loeb S, Braithwaite RS, Hayes RB.

Rev Urol. 2012;14(3-4):115-7. No abstract available.


Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J.

Eur Urol. 2013 Mar;63(3):585-7. doi: 10.1016/j.eururo.2012.11.047. Epub 2012 Dec 5. No abstract available.


A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J.

Genet Epidemiol. 2012 Jan;36(1):71-83. doi: 10.1002/gepi.21600.


Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.


Inherited susceptibility for aggressive prostate cancer.

Isaacs WB.

Asian J Androl. 2012 May;14(3):415-8. doi: 10.1038/aja.2011.146. Epub 2012 Apr 30. Review.


Utility of genome-wide association study findings: prostate cancer as a translational research paradigm.

Turner AR, Kader AK, Xu J.

J Intern Med. 2012 Apr;271(4):344-52. doi: 10.1111/j.1365-2796.2012.02522.x.


Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers.

Heald B, Edelman E, Eng C.

Eur J Hum Genet. 2012 May;20(5):547-51. doi: 10.1038/ejhg.2011.224. Epub 2012 Jan 4.


Predicting prostate cancer many years before diagnosis: how and why?

Vickers AJ, Lilja H.

World J Urol. 2012 Apr;30(2):131-5. doi: 10.1007/s00345-011-0795-8. Epub 2011 Nov 20.


Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer.

Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim ST, Sun J, Feng J, Duggan D, Carpten JD, Wiklund F, Grönberg H, Isaacs WB, Zheng SL, Xu J.

Carcinogenesis. 2011 Jul;32(7):1057-62. doi: 10.1093/carcin/bgr082. Epub 2011 May 5.

Items per page

Supplemental Content

Write to the Help Desk